Apr 1, 2024 11:09AM

Mar 14, 2024 04:15PM

Mar 11, 2024 05:05PM

Nov 29, 2023 06:09AM

Nov 8, 2023 07:30AM

Oct 25, 2023 08:30AM

Oct 25, 2023 08:30AM Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease

Oct 18, 2023 08:00AM

Sep 28, 2023 08:00AM

Sep 28, 2023 08:00AM

Aug 25, 2023 08:09AM

Aug 24, 2023 08:02AM

Aug 24, 2023 08:00AM

Jul 18, 2023 07:45AM Akebia Therapeutics (AKBA) Completed Type A Meeting with the FDA; Expects to Resubmit Vadadustat NDA in Q3 2023

Jul 18, 2023 07:45AM

Mar 2, 2022 12:53PM

Mar 1, 2022 04:01PM

Feb 22, 2022 03:50PM

Feb 22, 2022 08:31AM

Feb 22, 2022 08:30AM

Feb 9, 2022 08:30AM Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business Highlights

Nov 4, 2021 08:05AM

Oct 26, 2021 08:00AM

Oct 18, 2021 08:00AM

Aug 5, 2021 08:04AM

Aug 5, 2021 07:58AM

Jun 1, 2021 06:21AM

Jun 1, 2021 06:00AM Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All